BRCA1 and ovarian cancer: Somatic BRCA1/2 pathogenic variants are found to be present in up to 7% of ovarian cancers in the first line or platinum‐sensitive relapsed clinical setting (Alsop et al., 2012; Dann et al., 2012; Hennessy et al., 2010; McAlpine et al., 2012; Merajver et al., 1995; Yang et al., 2011).